Table 3 Comparison between the studied groups in monitoring parameters post treatment among moderate and severe COVID-19 patients.
Variable as (mean ± SD) | Group 1 (standard care) n = 40 | Group 2 (tocilizumab) n = 70 | Group 3 (tocilizumab/infliximab) n = 43 | Significance P value |
|---|---|---|---|---|
Time to improvement | 6.3 ± 4.1 | 5.9 ± 3.9 | 6.4 ± 4.8 | P = 0.097 |
Length of hospital stay | 10.3 | 8.9 | 7.6 | P = 0.03* |
PF | 228.7 ± 124.6 | 180.7 ± 62.4 | 210.8 ± 78.8 | P = 0.661 |
C-reactive protein (CRP) | 43.1 ± 7.5 | 46.8 ± 7.5 | 23.4 ± 8.2 | P = 0.004 |
Lactate dehydrogenase (LDH) | 297.2 ± 122.8 | 435.6 ± 56.4 | 457.1 ± 177.5 | P = 0.110 |
D-dimmer | 1.7 ± 1.03 | 2.15 ± 7.3 | 1.67 ± 3.2 | P = 0.185 |
Ferritin | 561.7 ± 27.1 | 1126.2 ± 86.4 | 937.9 ± 46.8 | P = 0.358 |
Total leucocytic count (TLC) | 10.4 ± 5.2 | 10.8 ± 5.4 | 11.2 ± 4.9 | P = 0.862 |
Absolute lymphocytic count (ALC) | 11.7 ± 5.9 | 13.6 ± 12.7 | 10.9 ± 10.8 | P = 0.04* |
Neutrophils lymphocytic ratio (NLR) | 8.9 ± 1.6 | 14.5 ± 1.8 | 10.1 ± 1.5 | P = 0.355 |
Alanine transaminase (ALT) | 71.4 ± 7.7 | 102.2 ± 24.7 | 140.7 ± 27 | P = 0.280 |
Aspartate transaminase (AST) | 56.2 ± 6.9 | 59.2 ± 4.6 | 112.1 ± 6.8 | P = 0.432 |
Troponin | 0.02 ± 0.014 | 0.003 ± 0.004 | 0.07 ± 0.012 | P = 0.527 |
